Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-label, Randomized, Single-dose, 3-Period, 3-Sequence Crossover Study to Assess the Relative Bioavailability of the Intended Commercial Formulation Versus the Previous MyoKardia Formulation of Danicamtiv and to Assess the Effect of Food on the Pharmacokinetics of the Intended Commercial Formulation in Healthy Adult Participants
Conditions
Interventions
Danicamtiv
Locations
1
United States
Anaheim Clinical Trials
Anaheim, California, United States
Start Date
September 5, 2023
Primary Completion Date
November 10, 2023
Completion Date
November 10, 2023
Last Updated
November 29, 2023
NCT07310264
NCT06342713
NCT07472361
NCT06649110
NCT06823947
NCT07240675
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions